Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Wednesday 13th November 2024. I am pleased to confirm the following.

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq) - 12
- Durvalumab (Imfinzi)-0
- Nivolumab (Opdivo)-6
- Pembrolizumab (Keytruda)-16
- Chemotherapy- 50
- Radiotherapy- no access to this information
- Chemotherapy AND Radiotherapy- no access to this information
- Osimertinib- 12

Q2. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin)-4
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)-0
- Lonsurf (Trifluridine - tipiracil)-0
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)- 10
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)- 6
- Any other systemic anti-cancer therapy- FLOT x 7, Trastuzumab Cisplatin Capecitabine -3
- Palliative care only- no access to this information
- Zolbetuximab (Vyloy)-0

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Co-ordinator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns.

Chief Executive: Joe Harrison
Chair: Heidi Travis